Indefinite Delivery Contract SPE2DR25D3013

The Indefinite Delivery Contract (IDC) SPE2DR25D3013, awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The $999,999,999 IDC has a period of performance through December 2026 and serves as a primary vehicle for the DLA to procure critical medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains.

The contract was competitively awarded under a pre-solicitation issued by the DLA in February 2024, which outlined plans to establish Pharmaceutical Prime Vendor Global Program Generation V contracts to provide worldwide pharmaceutical support to various DoD customers. The solicitation sought proposals for separate regional line items, with the intent to make multiple awards to ensure resilient access to vital pharmaceuticals during contingencies or natural disasters. AmerisourceBergen, as a prime contractor, will be responsible for furnishing the pharmaceutical products in accordance with the specified ordering, packaging, shipping, receiving, and unique requirements outlined in the solicitation.